Pacific Life Insurance Fit Review for Epilepsy and Seizure Disorders

Research Snapshot

Why Pacific Life Qualified for This Study

Questions This Section Answers

• Is Pacific Life a good choice for life insurance for epilepsy and seizure disorders?
• Why did only three of seven AI platforms name Pacific Life for epilepsy life insurance?

Pacific Life qualified because it cleared the study's minimum-mention threshold: three of seven platforms named it during ranking discovery, giving it a 42.9% share of included platform responses (anthropic, deepseek, kimi). It did not appear in the ranking-stage lists from openai, google, grok, or perplexity, so its inclusion rests on a minority of platforms rather than broad agreement.

The platforms that named it did so for different reasons. Anthropic cited Pacific Life's explicit listing of epilepsy/seizure as a condition reviewed in its accelerated underwriting program ^[1]. Deepseek cited its established individual life-insurance lineup of term, IUL, and VUL products ^[2]. Kimi cited its financial strength and permanent-product suite ^[3].

Pacific Life's final rank in this study is 6, reflecting a mixed fit rating overall. Three platforms rated it "good" (anthropic, google, kimi) and four rated it "mixed" (deepseek, grok, openai, perplexity). That split is the central finding of this review: Pacific Life is credible for well-controlled epilepsy, but no platform presented it as a leading epilepsy-specific carrier.

This review covers only Pacific Life's fit for Life Insurance for Epilepsy and Seizure Disorders. It is not a general company review.

The Product, Model, Plan, or Service Most Relevant to Life Insurance for Epilepsy and Seizure Disorders

Questions This Section Answers

• Which Pacific Life plan should a buyer with epilepsy choose if they want term coverage with conversion flexibility?
• Does Pacific Life's PL Promise Term allow conversion to permanent coverage without new medical underwriting after a seizure-related health change?

The most relevant Pacific Life product for this use case is PL Promise Term, a fully underwritten level-premium term policy available in 10-, 15-, 20-, 25-, and 30-year periods ^[4]. It is the product most platforms named, and it is the one with the clearest documented features relevant to a buyer with epilepsy.

PL Promise Term's public materials describe conversion of all or part of the death benefit to an available Pacific Life universal-life policy without new underwriting during the stated conversion period, subject to product and policy terms ^[6]. Independent reviews describe conversion rights running to age 65 or 70 depending on the source, which is a conflict buyers should verify in the actual contract ^[7].

Pacific Life also lists permanent alternatives: indexed universal life (IUL), variable universal life (VUL), universal life (UL), and guaranteed universal life (GUL) ^[9]. Platform-reported product names for this use case include PL Promise Term, Pacific Elite Term, IUL, VUL, and UL (anthropic, deepseek, kimi, openai, perplexity). One platform reported that Pacific Life does not offer traditional whole life or final expense coverage ^[10], while another platform's response listed PL Promise GUL among relevant products (google). That product-name conflict is unresolved in the supplied evidence and should be confirmed with a licensed agent.

What the AI Platforms Agreed About

Questions This Section Answers

• What do AI platforms agree on about Pacific Life's underwriting approach for epilepsy?
• Is Pacific Life's epilepsy underwriting process fully underwritten rather than no-exam?

Platforms broadly agreed on four points.

First, Pacific Life's public underwriting materials address epilepsy and seizures rather than ignoring the condition. One platform cited a Pacific Life underwriting guide stating that epilepsy/seizures are individually considered, with mild to moderate ratings typical and higher ratings or decline possible with complications ^[12]. Another cited a Pacific Life accelerated-underwriting document listing epilepsy/seizure as a condition reviewed ^[13].

Second, an epilepsy history generally pushes the case out of accelerated no-exam underwriting and into fuller review. One platform stated that epilepsy and seizure disorders are listed as major medical conditions that preclude accelerated underwriting and route applicants to modified or traditional pathways ^[14]. Another cited a Pacific Life accelerated-underwriting checklist identifying epilepsy/seizure as a condition that may preclude that route ^[16].

Third, underwriting will examine seizure type, frequency, time since the most recent seizure, medications, treatment compliance, neurological evaluation, and driving restrictions. Independent sources cited across platforms identify these as standard epilepsy underwriting factors ^[17].

Fourth, Pacific Life holds strong financial-strength ratings. One platform cited A+ (Superior) from AM Best, AA- from S&P Global, and Aa3 from Moody's ^[22]. Another cited A+ from AM Best, A1 from Moody's, and A+ from S&P and Fitch ^[23]. These two rating sets conflict on the Moody's and S&P figures, and buyers should confirm current ratings directly.

Where the AI Platforms Disagreed or Were Uncertain

Questions This Section Answers

• Do AI platforms disagree about whether Pacific Life is a good or mixed fit for epilepsy life insurance?
• Is it clear whether Pacific Life's accelerated underwriting applies to epilepsy applicants?

The platforms split on overall fit. Three rated Pacific Life "good" for this use case (anthropic, google, kimi) and four rated it "mixed" (deepseek, grok, openai, perplexity). No platform rated it poor, and no platform called it best-in-class for epilepsy.

The sharpest disagreement concerns accelerated underwriting. One platform reported that Pacific Life's accelerated program explicitly includes epilepsy/seizure as a condition reviewed and can cover up to $5 million with no medical exam for ages 18-50 ^[24]. Another platform reported the opposite framing: that epilepsy and seizure disorders are listed as conditions that preclude accelerated underwriting and route applicants to modified or traditional pathways ^[26]. A third platform described public materials as conflicting on how broad no-exam eligibility is, with some pages advertising no-exam underwriting and others indicating seizure history can preclude that route (perplexity). These are not reconcilable from the supplied evidence. The practical reading is that accelerated underwriting for an epilepsy applicant is uncertain and must be confirmed case by case.

Coverage limits also conflict. One platform cited accelerated underwriting up to $3 million for eligible applicants ages 18-60 ^[27]. Another cited up to $5 million for ages 18-50 ^[25]. A third cited no-exam eligibility up to $3 million for ages 18-80 ^[29]. These figures cannot all be current, and none is epilepsy-specific.

Pricing transparency is a shared uncertainty. No platform located a current, epilepsy-specific Pacific Life premium. One platform noted that the only Pacific Life pricing comparison it located was published in 2023 and was for a healthy applicant (openai). Another reported term rates running 4% to 20% below national averages per a 2026 analysis ^[30], while a different source said Pacific Life is not known for the cheapest term rates and that its strength is permanent insurance ^[31]. Both can be true, but neither is an epilepsy quote.

One platform disclosed a 2026 class-action settlement in which Pacific Life agreed to pay $58.3 million over allegations of misleading illustrations for its Pacific Discovery Xelerator IUL, with Pacific Life denying wrongdoing ^[32]. Another platform noted Pacific Life launched Pacific Horizon IUL 2 in 2025 as a consolidated replacement for prior IUL offerings ^[33]. Whether the settlement concerns apply to newer products is unresolved in the supplied evidence.

Use-Case-Specific Features and Capabilities

Questions This Section Answers

• What features make Pacific Life worth considering for a buyer with well-controlled epilepsy?
• Does Pacific Life publish epilepsy-specific rate classes or underwriting thresholds?

Pacific Life's relevant capabilities for this use case are underwriting pathways, conversion flexibility, product range, and financial strength. None of them is epilepsy-specific.

On underwriting pathways, Pacific Life describes accelerated, modified, and traditional underwriting. Its materials state that accelerated underwriting may provide up to $3 million of PL Promise Term coverage without a medical exam for eligible applicants ages 18-60 and standard-or-better risk classes, and that modified underwriting is described for all risk classes within stated age and coverage limits ^[34]. These are eligibility descriptions, not guarantees for seizure-disorder applicants.

On conversion, PL Promise Term materials describe conversion of all or part of the death benefit to an available Pacific Life universal-life policy without new underwriting during the stated conversion period ^[35]. For a buyer whose seizure control could worsen, this is the most concrete use-case benefit in the supplied evidence.

On product range, Pacific Life publicly lists term, IUL, VUL, UL, and GUL categories ^[36]. One platform reported that most applicants with a controlled seizure disorder qualify for IUL or GUL policies, though a table rating is likely ^[37]. That claim is marked inferred in the source catalog and should be treated as platform-reported rather than established.

On financial strength, platforms cited A+ (Superior) from AM Best and AA- from S&P Global ^[38], with a conflicting set citing A+ from AM Best, A1 from Moody's, and A+ from S&P and Fitch ^[39].

What Pacific Life does not publish, per the platforms, is equally important: no seizure-specific underwriting table, no epilepsy rate classes, no postponement periods, and no documentation standard (openai, deepseek, perplexity, kimi). One platform noted that public underwriting guides are older, spanning roughly 2021 to 2025, so 2026-specific epilepsy outcomes are unclear (grok).

Pricing, Fees, Contracts, and Ongoing Costs

Questions This Section Answers

• How much does Pacific Life cost per month for a buyer with epilepsy, and is any epilepsy-specific premium published?
• What fees, surrender charges, or conversion costs should a Pacific Life buyer with epilepsy confirm before signing?

No current, individualized Pacific Life premium for an applicant with epilepsy or another seizure disorder is publicly verifiable. Pricing confidence is low across the platforms that addressed it.

Premium depends on age, coverage amount, term length, tobacco status, state, underwriting class, seizure history, and other medical and lifestyle information (openai). One platform reported illustrative preferred non-tobacco pricing from a 2023 Pacific Life comparison document but explicitly warned that the example was for a healthy applicant and should not be used as an epilepsy quote (openai). Another reported sample PL Promise Term base rates for excellent-health nonsmokers of roughly $19 to $83 per month for $500,000 of 20-year coverage at ages 30 to 50, again not epilepsy-specific ^[40]. A third reported term rates running 4% to 20% below national averages per a 2026 analysis ^[41], while another source said Pacific Life is not known for the cheapest term rates ^[42].

Table ratings are the main cost variable for this use case. One platform reported that each table rating typically adds about 25% to standard premium, with epilepsy outcomes ranging from standard to Table 2 for 10+ years seizure-free, Table 2-4 at 5-10 years, Table 4-6 at 3-5 years, Table 6-8 at 2-3 years, and Table 8-10 or decline at 1-2 years ^[43]. Another platform reported Table 2-4 for seizure-free 2+ years on medication, Table 4-6 at 1-2 years, and Table 6 or decline within 12 months or for uncontrolled seizures ^[45]. These tables are industry frameworks, not Pacific Life's published rules, and they conflict at the margins.

On fees and contract terms, platform-reported items include rider charges that vary by rider and state, a possible administrative fee when the accelerated death-benefit feature is exercised (openai), attending-physician-statement costs that Pacific Life reimburses when using preferred providers (anthropic), and surrender charges on permanent products typically spanning 10 to 15 years (kimi). One platform reported a standard free-look period of typically 10 to 30 days depending on state (google). Another platform reported that public sources reviewed did not verify surrender charges, lapse terms, contestability details, or conversion deadlines for the relevant products (perplexity). Buyers should treat all fee figures as unverified until confirmed in a current illustration and policy contract.

Best Suited For

Questions This Section Answers

• Who is Pacific Life best suited for among buyers with epilepsy or a seizure disorder?
• Is Pacific Life a good fit for a buyer with well-controlled epilepsy who wants convertible term coverage?

Pacific Life is best suited for applicants with well-controlled, well-documented epilepsy who want individually underwritten term coverage and value future conversion flexibility.

Platforms converged on a similar profile: applicants seizure-free for roughly two or more years on stable medication, with documented treatment compliance and regular neurologist follow-up (anthropic, google, grok, kimi, openai). One platform described the sweet spot as applicants with stable or well-documented seizure histories who want a carrier capable of traditional underwriting and possible conversion to permanent coverage (openai). Another described buyers who want term coverage first with universal or permanent coverage as a secondary option (perplexity).

Secondary fits include buyers who want a large, financially strong insurer rather than a niche impaired-risk carrier (deepseek, kimi), buyers willing to complete full underwriting including medical records and a possible attending-physician statement (google), and buyers who may qualify for modified underwriting within stated age and coverage limits ^[46].

Probably Not Best Suited For

Questions This Section Answers

• Who should not choose Pacific Life for life insurance with epilepsy or a seizure disorder?
• Is Pacific Life a poor fit for a buyer with recent, frequent, or uncontrolled seizures?

Pacific Life is probably not the best fit for applicants with recent, frequent, uncontrolled, or poorly documented seizures, or for buyers who need guaranteed acceptance.

Platforms repeatedly flagged the same exclusions. Applicants with seizures within roughly the last 6 to 12 months face likely postponement or decline (anthropic, grok, google). Applicants with uncontrolled or breakthrough seizures despite medication face likely postponement or decline (anthropic, grok, kimi). Applicants with severe seizure types, status epilepticus history, or significant neurological comorbidities are directed toward specialized high-risk placement (anthropic, kimi).

Buyers seeking guaranteed-issue or simplified-issue coverage are also a poor fit. Multiple platforms noted that Pacific Life does not emphasize guaranteed-issue, simplified-issue, or final expense products for this condition (deepseek, kimi, grok). One platform reported that Pacific Life does not offer traditional whole life or final expense coverage at all ^[47], though another platform's response listed a GUL product, leaving that point unresolved.

Self-directed buyers are a poor fit as well. One platform reported that Pacific Life does not offer a direct-to-consumer online application and requires working with an independent financial professional ^[49]. Another described the same constraint as adding coordination time (anthropic).

When Another Option May Be Better

Questions This Section Answers

• When is a better alternative than Pacific Life the right choice for a buyer with epilepsy?
• Which carriers or product types should a buyer with uncontrolled seizures consider instead of Pacific Life?

Another option may be better in five situations the platforms described.

When the applicant has recent, frequent, or uncontrolled seizures. Platforms directed these buyers toward guaranteed-issue or impaired-risk specialists, naming Mutual of Omaha, AIG, and Gerber Life for guaranteed-issue consideration and describing graded-benefit final expense carriers as an alternative (kimi). One platform recommended specialized high-risk carriers or brokers experienced in declined-case placement (anthropic).

When the applicant needs a small coverage amount. One platform reported that final expense specialists offering level day-one coverage for controlled seizures, typically around $50 to $100 per month for $10,000, would be more directly accessible than Pacific Life ^[50].

When price is the primary decision factor. One platform recommended comparison quotes from Transamerica, Lincoln Financial, and Protective (anthropic). Another noted that if pure term coverage at the lowest price is the main goal, better options exist elsewhere ^[51].

When the buyer wants traditional whole life or guaranteed universal life. One platform reported that Pacific Life does not offer these products and suggested carriers offering GUL, naming Guardian and New York Life (anthropic). This conflicts with another platform's listing of PL Promise GUL and should be verified.

When the buyer wants a direct online application. One platform noted that online-first carriers may offer a faster digital experience than Pacific Life's agent-mediated process ^[52].

Questions to Verify Before Buying

Questions This Section Answers

• What should a buyer confirm with Pacific Life before signing a contract for epilepsy life insurance?
• How can a buyer verify Pacific Life's epilepsy underwriting outcome before submitting a formal application?

The platforms supplied overlapping verification lists. The consolidated items below are the ones most likely to change the outcome.

Confirm whether Pacific Life will provide an informal, non-binding underwriting review before a formal application, and whether the broker can submit the exact seizure history anonymously (openai). Ask how the company will classify the applicant based on seizure type, frequency, date of last seizure, age at diagnosis, cause, EEG or imaging results, medication changes, treatment compliance, and neurologist follow-up (openai, anthropic). Ask for the likely rating, postponement period, or decline risk for that exact history (openai, anthropic).

Confirm whether the seizure history qualifies for accelerated underwriting or requires full underwriting with a paramedical exam and attending-physician statement, and what the turnaround time is (anthropic, perplexity). Ask what documentation Pacific Life requires from the neurologist, including EEG results, imaging, treatment-compliance notes, and frequency assessment (anthropic, perplexity).

Confirm whether driving restrictions, license suspension, occupational limitations, or motor-vehicle records affect underwriting, since NAIC materials explain that accelerated underwriting may use external data such as prescription history and motor-vehicle records ^[53].

Confirm the conversion terms in writing: whether the proposed PL Promise Term policy allows conversion after a seizure-related health change, and what the deadline, product, age, and amount limitations are (openai, anthropic, kimi). Confirm the guaranteed premiums, renewal premiums, conversion charges, rider charges, and administrative fees in the actual state and policy illustration (openai, anthropic).

For IUL, VUL, or UL, request the guaranteed column in writing rather than the projected column, and ask about guaranteed values, nonguaranteed assumptions, surrender charges, loan provisions, lapse risks, and minimum premium requirements ^[54]. Confirm whether Pacific Life is licensed and the specific product approved in the applicant's state, including New York where availability may differ (openai).

Final AI Consensus Verdict

Mixed fit. Pacific Life is worth a broker-led preliminary submission for applicants with controlled, well-documented epilepsy who want term coverage and conversion flexibility. The evidence does not support calling it a leading epilepsy-specific choice, because its public materials do not reveal seizure-disorder underwriting criteria or current condition-specific pricing, and platforms disagreed about whether epilepsy precludes or merely complicates accelerated underwriting.

Three of seven platforms named Pacific Life in the ranking stage, at an average rank of 5.33 and a best rank of 2. Three platforms rated it good and four rated it mixed. The buyer should compare Pacific Life's informal underwriting result with several carriers before making a formal application, and should treat every pricing figure in this review as unverified until confirmed in a current illustration.

How This Review Was Produced

This review synthesizes fit-research responses from seven AI platforms that evaluated Pacific Life for life insurance with epilepsy or a seizure disorder. Three of those platforms named Pacific Life during ranking discovery, which is the basis for its inclusion. Each platform supplied its own citations, product names, pricing notes, and verification questions. The study research date is 2026-09-22. Platform-reported research dates differ: deepseek reported 2026-01-15, while the other six platforms reported 2026-09-22. All platform outputs are marked platform-reported and not independently verified.

Methodology Limitations

Platform-reported research dates differ from the authoritative run date, and deepseek's earlier date means its findings may be less current than the others. Deepseek also ran without search enabled, so its claims rest on model knowledge rather than retrieved sources.

The supplied URLs were collected from platform responses and were not independently validated by the writer stage. Citations are platform-reported evidence, not independently verified facts. No-search model claims require explicit verification before being described as current facts.

Pacific Life's public materials describe underwriting pathways and product features but do not disclose detailed epilepsy-specific decision rules. Independent sources describe common industry factors for epilepsy underwriting, but they do not prove Pacific Life's exact underwriting outcome. Product availability, riders, forms, conversion rights, and fees vary by state and may change; current policy forms and illustrations control. The research year is 2026, but the publicly available Pacific Life pricing comparison located was published in 2023 and is not a current or epilepsy-specific quote. Platform agreement on any point does not prove product quality.